Abstract There are lot of grey zones in Philadelphia negative chronic myeloproliferative neoplasms (CMPNs) and that's the reason they are in hit list of researchers. Having a spectrum of disorders their diagnosis is very important and especially to differentiate from each other since they overlap with each other in many ways. Diagnosis doesn't start from lab but with clinical phenotype. Clinical phenotype not only able to provide us the diagnosis but also helps in management of the disease per se. When diagnosis comes, the old timer but an evergreen morphology plays an important role which along with the newer generation tool ''molecular'' helps in differentiating these disorders. Lot of studies have already come up from the world. Indian data has also started coming up. When we say about the Indian data nothing holds more important role than Indian Society of Haematology and Blood Transfusion, ISHBT. This small review will cover all papers with BCR-ABL negative CMPNs which were presented at the annual national conference of the ISHBT (Haematocon 2017) which was conducted at Guwahati. These abstract papers from various reputed institutes and centres will provide a short academic journey towards ongoing research activities at these places and will able to guide us regarding Philadelphia negative CMPNs and also stimulate our brain for some left or conflicted areas.
Introduction
Chronic myeloproliferative neoplasms (CMPNs) which include polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) and other less well-characterized chronic myeloproliferative disorders are clonal diseases which originate in pluripotential haematopoietic stem cell. The clonal expansion results in an increased abnormal haematopoiesis thus producing group of interrelated syndromes which are then classified as per the predominant phenotypic expression of the clone. Numerous studies have been done recently in the field of CMPNs resulting in the incorporation of some major changes in WHO 2017 classification of hematolymphoid malignacies.
Methodology
A short review from abstracts comprising of research data pertaining to Philadelphia negative CMPNs from our country which were presented during Haematocon 2017 held from 2nd Nov 2017-05 Nov 2017 at Guwahati were being done. All abstracts presented as oral or in poster form were reviewed. All Philadelphia positive cases and mastocytosis cases were excluded.
Molecular Studies in CMPNs
Role of molecular studies in myeloproliferative neoplasms is progressing. While enough studies are available on JAK2 mutational analysis there are only few studies available for While no additional mutation other than four common mutations were identified by allele specific PCR it enabled to pick up two additional positive cases in their study, thus making it to have better sensitivity. This study is similar to other study [17] in which all MPL mutation positive cases were detected by allele-specific PCR, while 17 out of 58 (29%) low-level mutations were either difficult to identify or were completely missed by Sanger sequencing. Therefore, this study reflects that triple negative (JAK-2, MPL and CALR) needs a concern to be confirmed by allele specific PCR which is more sensitive and reliable for their detection especially if previously it has been done by direct sequencing. This study provides an important information regarding a simple and robust assay capable to detect the majority (approximately 98%) of MPL mutations AS allele-specific, LNA locked nucleic acid, RFLP, restriction fragment length polymorphism associated with PMF and ET with high analytical sensitivity (approximately 2.5%). Other methods described for the detection of MPL mutations are high-resolution melting, quantitative PCR, bead-based assay with locked nucleic acid modified probes, amplification refractory mutation, pyrosequencing and single allele-specific PCR and their sensitivity are either similar or lower than allelespecific PCR (approx 3-0.1%). Another major disadvantage among all these tests is that they failed to detect S505N mutation, which is present in a significant proportion (10.3%) of MPL mutation positive cases [18] .
JAK 2 and Its Association with Clinical Phenotype in MPNs
MPNs have been associated with thrombophilia which has been extensively reviewed by Pati et al. in their editorial [19] . These vascular events present in approx of 12-39% of PV and ET patients [20] . International Prognostic Score of Thrombosis in ET (IPSET) in 2012 introduced markers of thrombotic risk (age, cardiovascular risk factors, prior history of thrombosis) [21] . JAK2 mutation also now is considered a well-established risk factor for thrombosis in ET [21, 22] . Besides V617F allele burden has also been associated with acquired activated protein C resistance, low free PS and increased levels of soluble markers of endothelial and platelet activation including elevated tissue factor [23] [24] [25] . In continuation with these studies, a study from AIIMS [26] was presented with a paper titled ''Impact of Combined JAK2V617F Mutation and the Inherited Thrombophilic Factors on Thrombotic Risk in CMPNs'' to study the combined role of JAK2 V617F and inherited thrombophilia in hypercoagulative state in CMPN patients. A total of 131 CMPN patients (PV, PMF and ET) positive for JAK2 V617F with thrombosis and 85 controls (JAK2 V617F negative CMPN patients without thrombosis) were studied. The DNA samples were screened for inherited thrombophilia which included FV Leiden, MTHFR C677T polymorphism, PT 20210 mutation and deficiencies of Protein C, Protein S and AT III. There were 131 patients out of which 74 were males and 57 were females (M:F-2.3:1) with median age 52 years (range 16-85 years). In 37 (28.2%) patients combined JAK2 V617F and inherited thrombophilic factors (predominantly FV Leiden) were present as compared to 7/85 (8.2%) in controls. Among inherited thrombophilic factors FV Leiden mutation was exclusively present in JAK2 V617F positive patients and was negative in controls (p = 0.004), the frequency of MTHFR C677T polymorphism was higher in JAK2 V617F positive patients as compared to controls but the difference was not statistically significant (p \ 0.07) in the latter. Thus, the study emphasized that JAK2 V617F mutation in combination with inherited thrombophiliamay increase the risk of thrombosis in CMPN patients and thus this finding could further assist in risk stratification, setting up the investigation and treatment protocols in CMPN patients. Besides the association of JAK2 617F allelic burden with thrombosis; another fascinating aspect among the clinicians is an association of former with clinical phenotype. Recently a study by Shixiang et al. has studied an impact of JAK2 617F mutation burden on disease phenotype [27] in which they have found some conclusive results like, JAK2 V617F mutation burden in PV to be higher than ET; strong correlation of JAK2 V617F mutation allelic burden with WBC counts, haemoglobin level, splenomegaly, and thrombosis. There is paucity of data showing the association between JAK2V617F allele burden and clinical phenotype in Indian polycythemia vera (PV) patients. In continuation with it a study from AIIMS was done by Thus, the study showed that in PV patients higher JAK2 V617F allele burden was associated with increasing age, splenomegaly and thrombotic events. Therefore, authors have recommended that inclusion of JAK2 V617F allele burden by RQ-PCR may be considered for prognostication and setting up the treatment protocol in these patients. This study from India was similar to one International study by Alessandro et al. [29] .
Clincopathological Spectrum of MPNs
Another study by Tahlan et al. [30] which focussed on Clinico-Pathological Spectrum of Myeloproliferative Neoplasm was presented at the national haematology conference in 2017 in which 120 cases of myeloproliferative neoplasms diagnosed over a period of 12 years were reviewed. The clinical features including hepatosplenomegaly were noted. The haemogram findings and bone marrow aspiration and trephine findings were analyzed. They found that out of total 120 MPN cases, 97 were diagnosed as chronic myeloid leukaemia (CML), 6 as polycythemia vera (PV), 5 as essential thrombocythemia (ET), 11 as primary myelofibrosis (PMF) and 1 as chronic neutrophilic leukaemia (CNL). 53.3% of the patients in the study were male and 46.7% were female. The overall male-female ratio was 1.1:1. CML was the most common type of MPN followed by PMF. Fever was the most common clinical presentation (53.3%) followed by abdominal symptoms (34.2%). Haematological parameters and bone marrow aspiration and trephine biopsy findings were analysed for the various MPNs and were compared with previously published studies.
Does Morphology have a Role to Play Now in CMPNs?
A hallmark of the histopathological diagnosis of MPNs is the number, morphology and topography of megakaryocytes which can help in differentiating among each other. Keeping this in mind a study was done by Tanya et al. [31] in JIPMER and was presented as ''Megakaryocyte Morphology and Morphometry in Philadelphia Negative Myeloproliferative Neoplasms''. There is significant overlap in the clinical, haematological as well as morphological features of the various subtypes of Ph negative MPN. The importance of bone marrow trephine biopsy plays a major role in distinguishing various subgroups of Ph negative MPN. Study from JIPMER aimed to assess and compare the megakaryocytic morphology and morphometry in Ph negative MPN wherein all newly diagnosed (based on WHO 2008 criteria) cases of Ph negative MPNs (n = 22) between January 2014 and June 2017 were included, out of which 7 cases were of ET, 7 were of PMF, 8 were of PV. They studied the following parameters in their bone marrow trephine biopsy:
1. Morphology-Location, type, number of megakaryocyte/mm 2 , megakaryocytes in clusters, attached to trabeculae, intrasinusoidal megakaryocytes, megakaryocytes with naked nuclei, and showing emperipolesis along with megakaryocyte atypia and degree of marrow fibrosis. 2. Morphometric analysis was done on a minimum of 10 megakaryocytesin each case by Olympus Microscope using Progress(R)Capture Pro software at 409 and these parameters were assessed: (a) cytoplasmic major diameter (CMD), (b) nuclear major diameter (NMD), (c) nuclear to cytoplasmic area ratio, (d) nuclear circularity. They found that the number of megakaryocytes/mm 2 was found to be significantly high in ET as compared to PMF (8.6 vs 4.13; p \ 0.05).Megakaryocytes in both dense and loose clusters were seen more in ET as compared to PV and PMF. Paratrabecular location of megakaryocytes were more in PMF as compared to ET and PV. One of the case of PMF showed a very high number of intrasinusoidal megakaryocytes (45.3 megs/mm 2 ). Megakaryocytes with naked nuclei and with emperipolesis were commonly seen in all the cases. Atypia was seen in 4 out of 7 cases of PMF and none in ET and PV. The degree of fibrosis (using WHO 2008 criteria) was significantly high for PMF (7 out of 8 cases showed grade 3 fibrosis). 6 out of 8 cases of PV and 5 out of 7 cases of ET showed grade 1 fibrosis. The mean CMD for PV was 13.02 which was more than both ET and PMF. Hence, the cytoplasmic area was more in PV as compared to ET and PMF. PV showed more of cloudlike nuclei and the NMD for PV was more as compared to ET and PMF. ET showed more of staghorn type of nuclei. The nuclear to cytoplasmic area was more in PV as compared to ET and PMF. Summarising the study, the number of megakaryocytes/mm 2 and clustering was more in ET, large size of megakaryocytes was seen in PV, atypia and fibrosis was more in PMF. Thus, the studied showed despite of overlapping of MPNs the morphology and morphometry of megakaryocytes can lead to clue to reach the diagnosis in various Ph negative MPN. The similar study by Nataliya et al. [32] showed that in ET, megakaryocytes were the largest of all MPNs, nuclei were more polymorphic and were characterized by a less regular cytoplasmic outline compared with normal forms. Thiele et al. [33, 34] also observed the similar pattern. Nataliya et al. also showed that morphologic findings concerning megakaryocytes didn't support a close relationship between ET and PV which was also observed by Gianelli et al. [35] .
Conclusion
Abstracts from Haematocon 2017 covering broad spectrum of CMPNs have given in-depth knowledge as well as the update on this entity. Various massive Indian data has been coming from various established centres and this will enlightens mort ho the world literature in future. Importance of these data gains more importance because of different challenges and clinical scenarios in Indian population thus leading to difficulty in diagnosis. Forums are required to raise these concerns and as far as Indian setting is concerned Indian Society of Haematology and Blood Transfusion has an important role to play while conducting annual conferences. This mini review from abstract from an annual conference in 2017 has focused upon updates and knowledge on CMPNs.
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